Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study

详细信息    查看全文

• 作者：Young Hee Yoon (1)
  Ha Kyoung Kim (2)
  Hee Seong Yoon (3)
  Se Woong Kang (4)
  June-Gone Kim (1)
  Kyu Hyung Park (5)
  Young Joon Jo (6)
  Joo Yong Lee (1)
  Dong Hoon Lee (1)
  
• 关键词：Retinal vein occlusion ; Macular edema ; Duration of symptom ; Early treatment ; Korean patients
• 刊名：Japanese Journal of Ophthalmology
• 出版年：2014
• 出版时间：March 2014
• 年：2014
• 卷：58
• 期：2
• 页码：146-154
• 全文大小：347 KB
• 参考文献：1. Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med. 2010;363:2135-4. CrossRef
  2. Lim LL, Cheung N, Wang JJ, Islam FM, Mitchell P, Saw SM, et al. Prevalence and risk factors of retinal vein occlusion in an Asian population. Br J Ophthalmol. 2008;92:1316-. jo.2008.140640" target="_blank" title="It opens in new window">CrossRef
  3. Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(1094-01):e5.
  4. McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(1113-3):e15.
  5. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453-0. CrossRef
  6. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(1102-112):e1.
  7. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(1124-3):e1.
  8. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115-8. CrossRef
  9. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127:1101-4. CrossRef
  10. Yeh WS, Haller JA, Lanzetta P, Kuppermann BD, Wong TY, Mitchell P, et al. Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology. 2012;119:1190-. CrossRef
  11. Lee JY, Yoon YH, Kim HK, Yoon HS, Kang SW, Kim JG, et al. Baseline characteristics and risk factors of retinal vein occlusion: a study by the Korean RVO study group. J Korean Med Sci. 2013;28:136-4. CrossRef
  12. Kiernan DF, Hariprasad SM. Normative databases in SD-OCT: a status report. In: Retinal physician. http://www.retinalphysician.com/articleviewer.aspx?articleID=104438. Accessed 1 Apr 2012.
  13. Hanada N, Iijima H, Sakurada Y, Imasawa M. Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab. Jpn J Ophthalmol. 2012;56:165-4. CrossRef
  14. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Hartnett ME, et al. Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10. Ophthalmology. 2011;118:345-2. CrossRef
  15. Yunoki T, Miyakoshi A, Nakamura T, Fujita K, Fuchizawa C, Hayashi A. Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab. Jpn J Ophthalmol. 2012;56:159-4. CrossRef
  16. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, et al. Ranibizumab for macular edema due to retinal vein occlusions long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802-. CrossRef
  
• 作者单位：Young Hee Yoon (1)
  Ha Kyoung Kim (2)
  Hee Seong Yoon (3)
  Se Woong Kang (4)
  June-Gone Kim (1)
  Kyu Hyung Park (5)
  Young Joon Jo (6)
  Joo Yong Lee (1)
  Dong Hoon Lee (1)
  
  1. Department of Ophthalmology, Asan Medical Center, University of Ulsan, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea
  2. Department of Ophthalmology, Kangnam Sacred Heart Hospital, Hallym University, Seoul, Korea
  3. St. Mary’s Eye Clinic, Busan, Korea
  4. Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea
  5. Department of Ophthalmology, Seoul National University Bundang Hospital, Gyeonggi-do, Korea
  6. Department of Ophthalmology, Chungnam National University Hospital, Deajeon, Korea
  
• ISSN：1613-2246

文摘

Purpose To determine the correlation between the duration of macular edema (ME) and visual outcomes among Korean patients with retinal vein occlusion (RVO). Methods Multicenter, interventional case series. Treatment-naive patients (n?=?249) with branch or central RVO (BRVO/CRVO) and ME for <6?months were included. We assessed the correlation between the duration of ME and treatment outcomes including the mean logarithm of the minimum angle of resolution best-corrected visual acuity (logMAR BCVA) improvement, the proportion of patients achieving at least a 3-line gain in BCVA, and the mean reduction in central retinal thickness (CRT) at 6?months. Results One hundred and fifty-six patients with BRVO and 93 patients with CRVO were divided into five groups based on the duration of ME (<2, 2-?weeks, 1-, 2-, 3-?months); the mean baseline BCVA and CRT among the groups did not differ significantly. In BRVO, the mean logarithm of the minimum angle of resolution (logMAR) BCVA improvements in the groups were 0.51, 0.32, 0.17, 0.19, and 0.13, respectively (P?=?0.002). The respective percentages of at least 3-line gains were 64, 53, 39, 38, and 21?% (P?<?0.001). The BCVA didn’t significantly improve in CRVO. The decrease in CRT was not correlated significantly with the duration of ME in either disease. Conclusions Treatment of BRVO as early as 2?weeks after onset of ME enhanced the visual outcome; there was no correlation in the patients with CRVO. This finding supports the current trend favoring early treatment to obtain better visual outcomes in patients with BRVO.